-
Tongshu Gene Partners with LC Gene to Distribute Gene Mutation Detection Kit in China
•
China-based gene testing service providers Tongshu Gene and LC Gene Diagnostics (Hangzhou) Co., Ltd. have entered into a strategic partnership, under which Tongshu Gene will become the exclusive distributor of LC Gene’s human EGFR, BRAF, KRAS, ALK, and ROS1 gene mutation detection kit. The agreement leverages LC Gene’s proprietary technology…
-
3D Medicines’ 3D185 Receives Orphan Drug Designation for Gastric Cancer
•
China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving orphan drug designation (ODD) status from the US Food and Drug Administration (FDA) for its pipeline drug candidate 3D185. The designation was granted for the drug’s potential use in treating gastric cancer and gastroesophageal junction carcinoma (GC/GEJ). This marks the…
-
Ascletis Pharma Initiates Dosing in Phase I Trial for COVID-19 Treatment ASC11
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced the dosing of four healthy subjects in the first cohort of a multi-dose escalation Phase I clinical study for its oral 3-chymotrypsin-like protease (3CLpro) inhibitor ASC11, in combination with 100 mg ritonavir tablets. The study aims to evaluate the safety, tolerability, and…
-
Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines
•
Base Therapeutics, a Guangdong-based firm specializing in base editing and prime editing technologies, has reportedly raised “tens of millions” of US dollars in a Series A1 financing round. The funding was led by Great Eagle VC, with participation from Baidu Venture, Sincere Capital, GDHT Capital, SPARK VC, and existing investor…
-
ConceMed Raises Pre-Series A Funding to Expand Digestive Endoscope Pipeline
•
ConceMed, a Guangdong-based maker of digestive soft electronic endoscopes, has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. The funding was led by Cowin Capital, with participation from the National Innovation Center for Advanced Medical Devices. The proceeds will be used to accelerate the company’s…
-
Luye Pharma’s Rykindo Receives FDA Approval for Schizophrenia and Bipolar I Disorder
•
China-based Luye Pharma Group (HKG: 2186) has announced receiving market approval from the US Food and Drug Administration (FDA) for its extended-release injectable suspension Rykindo (risperidone). The drug is approved for the treatment of schizophrenia in adults and as a monotherapy or adjunctive therapy to lithium or valproate for the…
-
WuXi Biologics CEO Outlines Growth Amid Global Challenges at J.P. Morgan Conference
•
China-based WuXi Biologics (HKG: 2269) delivered a speech at the J.P. Morgan Healthcare Conference, where its chief executive officer (CEO) Chen Zhisheng outlined the company’s strategic direction and achievements. Despite negative global macroeconomic conditions and inclusion on the US unverified list, WuXi Biologics has maintained its business model and continued…
-
Hengrui’s Generic Cyclophosphamide Capsules Approved by China’s NMPA
•
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its generic version of cyclophosphamide, marketed as Endoxan by UK firm Hikma Pharmaceuticals USA Inc. The approval allows Hengrui to market its capsules for the treatment of a wide range of…
-
ReLive Biotechnologies Acquires Co.Don AG, Secures USD 36 Million for Expansion
•
Tissue engineering and regenerative medicine start-up ReLive Biotechnologies Ltd has announced the full acquisition of Germany-listed Co.Don AG (FRA: CNW), gaining rights to its cartilage repair cell therapy Spherox/Chondrosphere. The move comes as the Hong Kong-based company secured over USD 36 million in a Series A financing round led by…
-
Akeso’s Penpulimab Secures New Approval for Lung Cancer Indication
•
China-based Akeso Biopharma (HKG: 9926) has announced receiving another indication approval from the National Medical Products Administration (NMPA) for its PD-1 inhibitor penpulimab (AK105). The drug is now approved for the treatment of first-line or locally advanced/metastatic squamous non-small cell lung cancer (sqNSCLC) in combination with chemotherapy. This marks a…
-
Clover Biopharmaceuticals Plans COVID-19 Vaccine SCB-2019 Launch in China for 2023
•
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has provided updates on its plans for the commercialization of its COVID-19 vaccine SCB-2019 (CpG 1018/Alum) in China, with a strategic focus on 2023. The company expects to begin the commercial launch of SCB-2019 in multiple provinces and municipalities in China during the first…
-
JHM Biopharma Raises RMB100 Million to Expand Protein Drug Pipeline
•
Hangzhou-based protein drug developer JHM Biopharma has reportedly secured close to RMB100 million (USD14.9 million) in a Series A+ financing round. The funding was led by 3E Bioventures and Guangdian Capital. Proceeds from the round will be allocated towards the development and expansion of JHM Biopharma’s product pipeline, as well…
-
Sino Biopharma’s PD-L1 Combo with Anlotinib Accepted for Review by China’s CDE
•
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its New Drug Application (NDA) filing for the combination of its anti-PD-L1 monoclonal antibody (mAb) TQB2450 and anlotinib has been accepted for review by the Center for Drug Evaluation (CDE). The Phase III study for this combination in first-line small cell…
-
Meheco’s Genertec Partners with AstraZeneca for COVID-19 Antibody Evusheld in China
•
China Meheco Group Co., Ltd (SHA: 600056) announced that its subsidiary Genertec Meheco has entered into a partnership with UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) to handle the import and distribution of Evusheld (tixagevimab, cilgavimab) in mainland China. Evusheld is a COVID-19 prophylactic neutralizing antibody combination designed to provide…
-
Guangzhou’s Overseas Pharma Wins China Clinical Trial Approval for OPL-038
•
Guangzhou-based Overseas Pharmaceuticals, Ltd has secured clinical trial approval in China for its sustained and controlled release drug OPL-038. The drug, filed as an Investigational New Drug (IND) under Category 2 (modified drug), aims to address the needs of adult patients with type 2 diabetes through a novel combination therapy.…
-
Eyougene Raises Hundreds of Millions in Series B Funding for Expansion
•
Eyougene Co., Ltd, a digital Contract Development and Manufacturing Organization (CDMO) based in Shanghai, has reportedly raised “hundreds of millions” of renminbi in a Series B financing round. The funding was led by Hangzhou Point Investment Management, with a contribution from Lingdu Capital. The proceeds will be used for research…
-
LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion
•
Shanghai LePure Biotech Co., Ltd, a China-based biotechnology company, has reportedly raised “hundreds of millions” of renminbi in a Series C financing round. The funding was led by Novo Holdings, General Atlantic, and Goldman Sachs Asset Management, with additional participation from HLC, Bayland Capital, HM Capital, Cas Holding, and TDF…
-
Shenzhen Keyto Fluid Control Secures Series C Funding for Expansion
•
Shenzhen Keyto Fluid Control Co., Ltd, a China-based manufacturer of precision fluid control components, has reportedly raised over RMB 100 million (USD 14.86 million) in a Series C financing round. The funding was led by Kinghall Ventures, with contributions from Hawkins Capital and Plow Capital. The proceeds will be used…
-
Xinhua Pharma’s OAB-14 Receives NMPA Approval for Phase I Alzheimer’s Study
•
China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) has announced receiving approval from the National Medical Products Administration (NMPA) to initiate a Phase I clinical study of its innovative Alzheimer’s disease (AD) drug, OAB-14. The study will assess the safety and tolerability, pharmacokinetics, pharmacodynamics, and food effects of OAB-14 in…
